SILVER SPRING, Md. — A panel of medical experts recommended Tuesday that the Food and Drug Administration approve a new way of treating opioid addicts, using a slender rod implanted into the arm that delivers medicine for months at a time, according to today's New York Times. Some doctors say [...]
The biggest winners--and losers--in the 2015 race for new drug approvals Let's start with the good news. In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. The new generational high, easily lapping [...]
Role of the FDA in Affordability of Off-Patent Pharmaceuticals Jeremy A. Greene, MD, PhD; Gerard Anderson, PhD; Joshua M. Sharfstein, MD In recent weeks, the increasing prices of off-patent pharmaceuticals have been the subject of extensive news coverage and debate, a public meeting at the Department of Health and Human Services (HHS), and hearings in [...]
Pharmacologic Therapy for Post Traumatic Stress Disorder: Review of Prescriptions and Potential Drug-Drug Interactions in a Military Cohort Kara L. Jablonski, PharmD, BCPS; Maria D. Devore, MS; Margaret A. Ryan, MD, MPH; Emily L. Streeter, PsyD, MPH, CPH; Jerlyn C. Tolentino, BA; Angelica A. Klinski, PharmD; and Nahed Bahlawan, PharmD, [...]
What Will Health Care Look like in 20-Years? The Microbiome: Beyond the Gut The Microbiome/Inflammation/Infection Link The Microbiome/Environment Link Genomics: The Revolution We've All Been Waiting For Pharmacogenomics Medicine Goes Mobile Immunotherapy ... and more Courtesy Medscape The Microbiome: Beyond the Gut Understanding of the world beneath—the seething, teeming microbial [...]
At the American College of Rheumatology (ACR) annual meeting, a neurologist and a rheumatologist took the stage to debate whether or not opioid analgesic medications belong in the management of chronic, noncancer pain.[1] John Markman, MD, a neurologist at the University of Rochester Medical Center, took the pro position; Daniel [...]
The results of this meta-analysis demonstrate that serum IGF-1 levels were significantly higher in de novo, drug-naïve PD patients compared with healthy controls. Nevertheless, additional endeavors are required to further explore the association between serum IGF-1 levels and diagnosis, prognosis and early therapy for PD.
PHILADELPHIA — New open-label data from the expanded-access treatment program involving the cannabidiol Epidiolex (GW Pharma) show the median reduction in frequency of convulsive seizures after 3 months of treatment was 45% in all patients but higher in those with Dravet syndrome, among the most severe types of epilepsy. The [...]
The US Food and Drug Administration (FDA) has approved a chewable tablet form of extended-release methylphenidate (QuilliChew ER, Pfizer Inc) for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older, the company announced today. The chewable product will be available in tablet form in strengths of 20, 30, and [...]
HUNTINGTON BEACH, California ― Results of a large, multicenter, randomized trial show that extended-release (ER) naltrexone (Vivitrol, Alkermes, Inc) can effectively prevent opioid relapse among a particularly vulnerable population: adults involved in the criminal justice system. "Extended-release naltrexone is better known now, but this study began prior to its approval [...]